SCP
CLNN icon

SymBiosis Capital Partners’s Clene CLNN Stock Holding History

SymBiosis Capital Partners’s Portfolio CLNN Stock Details CLNN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.13M Sell
431,094
-339,401
-44% -$1.74M 4.03% 5
2025
Q4 		$4.52M Buy
+770,495
New +$6.4M 4.13% 9

Other funds holding CLNN

BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SM
Scoggin Management New York $1.04B AUM 232.32% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Lunt Capital Management Holladay, Utah $260M AUM 10.98% 1-Year Est. Return
PEAK6
PEAK6 Chicago, Illinois $42.6B AUM 66.3% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SymBiosis Capital Partners's CLNN Position: Q1 2026 in Review

SymBiosis Capital Partners reduced its Clene (CLNN) stake by 44% in Q1 2026, selling an estimated $1.74M and leaving 431,094 shares worth $2.13M. The position accounts for 4.03% of the portfolio, ranked #5.

SymBiosis Capital Partners first reported a position in CLNN in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.52M in Q4 2025. 29 funds tracked by Wall St. Rank hold CLNN as of Q1 2026.

  • SymBiosis Capital Partners held 431,094 shares of Clene worth $2.13M as of Q1 2026.
  • SymBiosis Capital Partners sold 339,401 Clene shares in Q1 2026, an estimated $1.74M.
  • Clene made up 4.03% of SymBiosis Capital Partners's portfolio in Q1 2026, its #5 holding.
  • SymBiosis Capital Partners first reported a position in Clene in Q4 2025 and has held it in 2 quarters since.
  • SymBiosis Capital Partners's Clene position peaked at $4.52M in Q4 2025.
  • 29 funds tracked by Wall St. Rank held Clene as of Q1 2026.

Based on SymBiosis Capital Partners's 13F filing for Q1 2026, filed 12 May 2026.